Aptose Biosciences Launches New $50M ATM Offering, Terminates Old One
Ticker: APTOF · Form: 8-K · Filed: Jan 30, 2024 · CIK: 882361
Complexity: simple
Sentiment: bearish
Topics: equity-offering, capital-raise, dilution, at-the-market
TL;DR
**Aptose just set up a new $50M stock sale plan, expect potential dilution.**
AI Summary
Aptose Biosciences Inc. entered into a new "at-the-market" (ATM) equity offering sales agreement on January 25, 2024, with B. Riley Securities, Inc. and Stifel, Nicolaus & Company, Incorporated. This agreement allows Aptose to sell up to $50 million of its common shares through these agents. Simultaneously, Aptose terminated its previous ATM agreement from December 2022, which had $25 million remaining capacity. This matters to investors because it signals Aptose's intent to raise significant capital by selling new shares, which could dilute the value of existing shares and potentially pressure the stock price.
Why It Matters
This new ATM offering provides Aptose Biosciences with a flexible way to raise capital, but it also means more shares could be issued, potentially diluting current shareholders and impacting the stock price.
Risk Assessment
Risk Level: medium — The potential for significant share dilution through the $50 million ATM offering presents a medium risk to existing shareholders.
Analyst Insight
A smart investor would monitor the volume and pricing of shares sold under this new ATM offering to gauge the extent of dilution and its impact on the stock. Consider the company's cash burn rate and future capital needs in light of this financing strategy.
Key Numbers
- $50 million — New ATM Offering Capacity (The maximum amount of common shares Aptose Biosciences can sell under the new agreement.)
- $25 million — Remaining Old ATM Capacity (The unused capacity on the previous ATM agreement that was terminated.)
Key Players & Entities
- Aptose Biosciences Inc. (company) — the registrant filing the 8-K
- B. Riley Securities, Inc. (company) — sales agent for the new ATM offering
- Stifel, Nicolaus & Company, Incorporated (company) — sales agent for the new ATM offering
- $50 million (dollar_amount) — maximum aggregate offering price of common shares under the new ATM agreement
- January 25, 2024 (date) — date of the new ATM agreement and termination of the old one
- $25 million (dollar_amount) — remaining capacity on the terminated ATM agreement from December 2022
Forward-Looking Statements
- Aptose Biosciences will utilize a significant portion of the $50 million ATM offering. (Aptose Biosciences Inc.) — medium confidence, target: 2025-01-25
- The stock price of Aptose Biosciences will experience downward pressure due to potential dilution. (Aptose Biosciences Inc.) — medium confidence, target: 2024-07-25
FAQ
What is the purpose of Aptose Biosciences Inc.'s new "at-the-market" equity offering sales agreement?
The purpose of the new ATM agreement is to allow Aptose Biosciences Inc. to sell up to $50 million of its common shares from time to time through B. Riley Securities, Inc. and Stifel, Nicolaus & Company, Incorporated, acting as sales agents.
Which financial institutions are acting as sales agents for Aptose Biosciences Inc. in this new ATM offering?
B. Riley Securities, Inc. and Stifel, Nicolaus & Company, Incorporated are acting as sales agents for Aptose Biosciences Inc. in this new ATM offering, as stated in the filing on January 25, 2024.
What was the status of Aptose Biosciences Inc.'s previous "at-the-market" equity offering sales agreement?
Aptose Biosciences Inc. terminated its previous "at-the-market" equity offering sales agreement, dated December 2022, which had approximately $25 million of remaining capacity, concurrently with entering into the new agreement on January 25, 2024.
On what date did Aptose Biosciences Inc. enter into the new ATM agreement and terminate the old one?
Aptose Biosciences Inc. entered into the new ATM agreement and terminated the old one on January 25, 2024, as indicated by the 'Date of earliest event reported' in the filing.
What is the maximum aggregate offering price of common shares that Aptose Biosciences Inc. can sell under the new ATM agreement?
Under the new ATM agreement, Aptose Biosciences Inc. can sell common shares with a maximum aggregate offering price of up to $50 million.
Filing Stats: 1,885 words · 8 min read · ~6 pages · Grade level 11.6 · Accepted 2024-01-29 21:44:02
Key Financial Figures
- $1.71 — at a combined public offering price of $1.71 per common share and Warrant (the " Off
- $9.0 million — Aptose expects to receive approximately $9.0 million in net proceeds from the Offering (incl
- $2 — on shares at a price per share equal to $2.1375, (including warrants issued pursua
- $4.0 million — nd Hanmi agreed to purchase from Aptose $4.0 million of Aptose's common shares and warrants
- $1.90 — n share and 1.11111106 warrants will be $1.90. Each Warrant will be exercisable until
- $280,000 — tment, resulting in Newbridge receiving $280,000 in cash and 147,368 warrants, each exer
- $2.1375 — able for one common share at a price of $2.1375 per share. Each Warrant will be exercis
Filing Documents
- d742545d8k.htm (8-K) — 40KB
- d742545dex11.htm (EX-1.1) — 281KB
- d742545dex41.htm (EX-4.1) — 81KB
- d742545dex42.htm (EX-4.2) — 81KB
- d742545dex43.htm (EX-4.3) — 101KB
- d742545dex44.htm (EX-4.4) — 105KB
- d742545dex101.htm (EX-10.1) — 240KB
- d742545dex102.htm (EX-10.2) — 80KB
- d742545dex103.htm (EX-10.3) — 8KB
- g742545g0125232941976.jpg (GRAPHIC) — 4KB
- g742545g0125232942101.jpg (GRAPHIC) — 3KB
- g742545g0125232942211.jpg (GRAPHIC) — 1KB
- 0001193125-24-018524.txt ( ) — 1415KB
- apto-20240125.xsd (EX-101.SCH) — 2KB
- apto-20240125_lab.xml (EX-101.LAB) — 17KB
- apto-20240125_pre.xml (EX-101.PRE) — 11KB
- d742545d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 1.1 Underwriting Agreement 4.1 Form of Hanmi Warrant 4.2 Form of Placement Agent Warrant 4.3 Form of Public Offering Warrant 4.4 Form of Underwriter Warrant 10.1* Subscription Agreement 10.2* Amended and Restated Investor's Rights Agreement 10.3 Funding Satisfaction Agreement 104 Cover Page Interactive Data File (formatted as inline XBRL) * Certain portions of this Exhibit have been redacted pursuant to Item 601(b)(10) of Regulation S-K SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: January 29, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer